ˇ 1975 - Mouse monoclonal antibodies isolated in Nobel Prize winning work by Dr César Milstein and Dr Georges Köhler, at the
MRC Laboratory of Molecular Biology (LMB), Cambridge, UK.
ˇ 1980 - MRC know - how helps establish Celltech , the fore runner of the UK biotech industry. Celltech later sold its
world-leading monoclonal antibodies manufacture contract to Lonza A.G.
ˇ 1986 - LMB scientists Dr Michael Neuberger and Dr Greg Winter pioneer techniques to "humanise" mouse monoclonal
antibodies, making them better suited to human medical use.
ˇ 1989 Dr Neuberger, together with Dr Marianne Brüggemann of the BBSRC Babraham Institute, genetically engineers mice
to produce fully human antibodies.
ˇ 1990 Dr Winter's team at LMB and the Cambridge MRC Centre for Protein Engineering (CPE) develops and patents test-tube
production of human antibodies. M RC spin-out company, Cambridge Antibody Technology, founded to commercially exploit the
new technology. MRC special grant helps Drs Geoff Hale and Herman Waldmann found the Cambridge Therapeutic Antibody Centre
(TAC) to develop therapies using LMB mAbs.
ˇ 1995 TAC moves to Oxford to continue its MRC supported work.
ˇ 2000 Over 200 companies world-wide are marketing, or developing, research, diagnostic and therapeutic monoclonal antibodies
applications, many based on innovative MRC technology.
From the timeline we can see what progress has been made on research for monoclonal antibodies. Also it allows us to only
assume that the future technologies will ring more advances in this research.